GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » Additional Paid-In Capital

Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Additional Paid-In Capital : €255.1 Mil(As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Additional Paid-In Capital?


Biocytogen Pharmaceuticals (Beijing) Co's quarterly additional paid-in capital declined from Jun. 2023 (€256.7 Mil) to Dec. 2023 (€255.8 Mil) but then stayed the same from Dec. 2023 (€255.8 Mil) to Jun. 2024 (€255.1 Mil).

Biocytogen Pharmaceuticals (Beijing) Co's annual additional paid-in capital increased from Dec. 2021 (€210.6 Mil) to Dec. 2022 (€269.7 Mil) but then declined from Dec. 2022 (€269.7 Mil) to Dec. 2023 (€255.8 Mil).

Biocytogen Pharmaceuticals (Beijing) Co Additional Paid-In Capital Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Additional Paid-In Capital Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
- 210.59 269.70 255.80

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Additional Paid-In Capital Get a 7-Day Free Trial - 269.70 256.71 255.80 255.06

Biocytogen Pharmaceuticals (Beijing) Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Biocytogen Pharmaceuticals (Beijing) Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » Additional Paid-In Capital
Comparable Companies
HKSE:01521 HKSE:09966 HKSE:02105 HKSE:01477 HKSE:01672 HKSE:02616 HKSE:02256 HKSE:00775 HKSE:02157 HKSE:02179 VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
02315:Hong Kong
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Website
https://www.biocytogen.com.cn
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines